EUVIMEDEUVIMED entdecken
Crossref

Outcomes Associated With Blastomycosis in Solid Organ and Hematopoietic Cell Transplant Recipients

Vaisak O Nair iD, Bradley Johnson, Paschalis Vergidis iD, Nischal Ranganath iD

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.14430 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Vaisak O Nair und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Blastomycosis, Hematopoietic Stem Cell Transplantation, Organ Transplantation, Transplant Recipients. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

With reports of expanding epidemiology of blastomycosis across the United States, the purpose of this study was to evaluate the incidence and outcomes associated with blastomycosis in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients.

Methods

We conducted a retrospective case series of adult SOT and HCT recipients at a tertiary care medical center between January 1, 2005 and September 30, 2023. Cases were defined as culture‐proven blastomycosis. We performed descriptive statistical analysis to evaluate diagnosis, management, and outcomes (mortality) of blastomycosis in SOT.

Results

The cumulative incidence of blastomycosis was 0.11% with a median time to infection following transplant of 743 days. Of the 19 cases, the majority of patients were SOT recipients (90%). Supratherapeutic immunosuppression within 30 days of diagnosis was observed in 42% of cases with documented drug monitoring. Urine antigen testing was highly sensitive (100%). Fourteen (73.7%) patients received induction therapy with liposomal amphotericin B followed by azole therapy for a minimum of 12 months. Despite appropriate treatment, 1‐year mortality was high at 26.3%, with attributable mortality of 21.1%.

Conclusions

While rates of blastomycosis remain low among SOT and HCT recipients, infection is associated with poor posttransplant outcomes. Antigen testing can aid in timely assessment of disease severity and initiation of appropriate therapy. Among survivors, no relapses were observed while on lifelong secondary suppression. Future studies should aim to better define risk factors associated with developing blastomycosis and establish effective strategies for prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BlastomycosisHematopoietic Stem Cell TransplantationOrgan TransplantationTransplant RecipientsHumansMaleRetrospective StudiesFemaleMiddle AgedAdultAntifungal AgentsIncidenceAgedYoung Adult

Stichwörter der Autor:innen

blastomycosishematopoietic cell transplantationimmunosuppressionsolid organ transplantation

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • Department of Medicine, Section of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Quantitative Health Sciences, Division of Clinical Trials & Biostatistics, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Vaisak O Nair, Paschalis Vergidis, Nischal Ranganath

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences

Zitieren

APA

Nair, V. O., Johnson, B., Vergidis, P., & Ranganath, N. (2025). Outcomes Associated With Blastomycosis in Solid Organ and Hematopoietic Cell Transplant Recipients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14430

Vancouver

Nair VO, Johnson B, Vergidis P, Ranganath N. Outcomes Associated With Blastomycosis in Solid Organ and Hematopoietic Cell Transplant Recipients. Transplant Infectious Disease. 2025. doi:10.1111/tid.14430

BibTeX
@article{Nair2025,
  author = {Nair, Vaisak O and Johnson, Bradley and Vergidis, Paschalis and Ranganath, Nischal},
  title = {Outcomes Associated With Blastomycosis in Solid Organ and Hematopoietic Cell Transplant Recipients},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.14430}
}
Kostenlos starten →